Gilead Sciences, Inc. GILD announced today that the Marketing
Authorisation Application for the Quad single-tablet regimen of
elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for
the treatment of HIV-1 infection in adults, submitted on November 24, 2011,
has been validated by the European Medicines Agency. Review of the MAA
will be conducted under the centralized licensing procedure, which, when
finalized, provides one marketing authorization in all 27 member states of the
European Union.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in